MedTrace Logo

A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009）

NCT04420130 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2022-10-04

No results posted yet for this study

Summary

This is a a single-arm, prospective study of Camrelizumab combined with ablation and chemotherapy for patients with Pancreatic cancer liver metastasis.

The main purpose of this study is to evaluate the safety and tolerability of Camrelizumab combined with ablation and chemotherapy as a treatment of Pancreatic cancer liver metastasis.

Conditions

Interventions

DRUG

Camrelizumab

Camrelizumab was administered 200mg iv every 3 weeks

DRUG

Chemotherapy

The chemotherapy regimen may be a standard regimen for routine treatment of advanced pancreatic cancer.

PROCEDURE

Ablation

First give pancreatic cancer patients with liver metastases to ablation of liver metastases

Sponsors & Collaborators

  • Yanqiao Zhang

    lead OTHER

Principal Investigators

  • Yanqiao Zhang, PhD · Harbin Medical University Cancer Hosptital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2022-08-01
Completion
2023-08-01

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04420130 on ClinicalTrials.gov